Featured article

3D midbrain organoid model development

The drug development path—from hit discovery to the clinical space—relies on accurate experimental data that are predictive of outcomes in downstream settings. Increasing the complexity of disease models with 3D organoids in the early stages of drug discovery is an approach that provides a more relevant cellular context and potentially more accurate physiological data in orthogonal experiments. The development of 3D organoids that better represent the corresponding organ complexity enables researchers to better scale experiments, make data-driven decisions, and systemize those processes to speed discovery.

Read the full article
See the current issue, BioProbes 81